SEVELAMER

Course overview

CHRONIC KIDNEY DISEASE (CKD) PRESENTS A SIGNIFICANT CLINICAL CHALLENGE DUE TO COMPLICATIONS SUCH AS HYPERPHOSPHATEMIA, WHICH IS CLOSELY LINKED TO SECONDARY HYPERPARATHYROIDISM, VASCULAR CALCIFICATION, AND INCREASED CARDIOVASCULAR MORBIDITY AND MORTALITY. SEVELAMER, A NON-CALCIUM, NONMETAL PHOSPHATE BINDER, IS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION (FDA) AND IS USED TO MANAGE HYPERPHOSPHATEMIA IN CKD PATIENTS, ESPECIALLY THOSE ON DIALYSIS. UNLIKE CALCIUM-BASED BINDERS, SEVELAMER LOWERS SERUM PHOSPHATE LEVELS WITHOUT CAUSING HYPERCALCEMIA, THEREBY REDUCING THE RISK OF VASCULAR CALCIFICATION, WHICH IS A SIGNIFICANT CONCERN FOR THESE PATIENTS.IN ADDITION TO CONTROLLING PHOSPHATE LEVELS, SEVELAMER OFFERS BENEFITS SUCH AS IMPROVED LIPID PROFILES AND POTENTIALLY LOWER ALL-CAUSE MORTALITY. CLINICAL STUDIES HIGHLIGHT SEVELAMER'S VALUE AS A MULTIFACETED THERAPEUTIC AGENT DUE TO ITS EFFECTS ON LIPID METABOLISM AND MORTALITY REDUCTION. SEVELAMER'S FAVORABLE SAFETY PROFILE, WITH A LOWER RISK OF CALCIUM OVERLOAD-RELATED COMPLICATIONS, MAKES IT PARTICULARLY SUITABLE FOR PATIENTS AT HIGHER RISK OF CARDIOVASCULAR EVENTS. KDIGO GUIDELINES RECOMMEND SEVELAMER FOR CKD STAGES 3 TO 5, AND IT IS ALSO USED OFF-LABEL IN PEDIATRICS TO REDUCE PHOSPHATE ABSORPTION IN NUTRITIONAL FORMULAS. THIS ACTIVITY REVIEWS THE MECHANISM OF ACTION, CLINICAL EFFICACY, AND EXPANDING ROLE OF SEVELAMER IN CKD MANAGEMENT, OFFERING HEALTHCARE PROVIDERS THE LATEST EVIDENCE AND PRACTICAL INSIGHTS TO ENHANCE PATIENT OUTCOMES.